 | • レポートコード：MRC2305C154 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、238ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に7,732.83百万ドルであった世界の乾癬治療薬市場規模が、2022年には8,644.53百万ドルに成長し、その後年平均11.96％拡大して2027年には15,236.31百万ドルに達すると予測しています。本調査資料では、乾癬治療薬の世界市場について総合的に調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、治療薬分類別（インターロイキン阻害剤、腫瘍壊死因子阻害剤）分析、治療種類別（生物学的製剤、低分子全身薬、局所療法）分析、投与経路別（経口、非経口、局所）分析、用途別（関節炎、赤皮症、滴状乾癬、間擦性湿疹、膿疱性乾癬）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの内容をまとめました。なお、本書内の企業情報には、AbbVie Inc.、Amgen Inc.、AstraZeneca PLC、Bausch Health Companies Inc.、Biogen Idec、C.H. Boehringer Sohn AG & Ko. KG、Celgene Corporation、Dr.Reddy's Laboratories、Eli Lilly and Company、Forward Pharma、Johnson & Johnson Services, Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の乾癬治療薬市場規模：治療薬分類別 - インターロイキン阻害剤の市場規模 - 腫瘍壊死因子阻害剤の市場規模 ・世界の乾癬治療薬市場規模：治療種類別 - 生物学的製剤の市場規模 - 低分子全身薬の市場規模 - 局所療法の市場規模 ・世界の乾癬治療薬市場規模：投与経路別 - 経口薬の市場規模 - 非経口薬の市場規模 - 局所薬の市場規模 ・世界の乾癬治療薬市場規模：用途別 - 関節炎における市場規模 - 赤皮症における市場規模 - 滴状乾癬における市場規模 - 間擦性湿疹における市場規模 - 膿疱性乾癬における市場規模 ・世界の乾癬治療薬市場規模：地域別 - 南北アメリカの乾癬治療薬市場規模 アメリカの乾癬治療薬市場規模 カナダの乾癬治療薬市場規模 ブラジルの乾癬治療薬市場規模 ... - アジア太平洋の乾癬治療薬市場規模 日本の乾癬治療薬市場規模 中国の乾癬治療薬市場規模 インドの乾癬治療薬市場規模 韓国の乾癬治療薬市場規模 台湾の乾癬治療薬市場規模 ... - ヨーロッパ/中東/アフリカの乾癬治療薬市場規模 イギリスの乾癬治療薬市場規模 ドイツの乾癬治療薬市場規模 フランスの乾癬治療薬市場規模 ロシアの乾癬治療薬市場規模 ... - その他地域の乾癬治療薬市場規模 ・競争状況 ・企業情報 |
The Global Psoriasis Drugs Market size was estimated at USD 7,732.83 million in 2021 and expected to reach USD 8,644.53 million in 2022, and is projected to grow at a CAGR 11.96% to reach USD 15,236.31 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Psoriasis Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Therapeutic Class, the market was studied across Interleukin Inhibitors and Tumor Necrosis Factor Inhibitor.
Based on Type of Treatment, the market was studied across Biologic Drugs, Small Molecule Systemic Drugs, and Tropical Therapies.
Based on Mechanism of Action, the market was studied across Interleukin Inhibitors, PDE4 Inhibitors, and TNF Alpha Inhibitors.
Based on Route of Administration, the market was studied across Oral, Parenteral, and Topical.
Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
Based on Application, the market was studied across Arthritis, Erythrodermic, Guttate, Intertriginous, Nail, Plaque, and Pustular.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Psoriasis Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Psoriasis Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Psoriasis Drugs Market, including AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bausch Health Companies Inc., Biogen Idec, C.H. Boehringer Sohn AG & Ko. KG, Celgene Corporation, Dr.Reddy’s Laboratories, Eli Lilly and Company, Forward Pharma, Johnson & Johnson Services, Inc., Leo Pharma AS, Merck & Co., Inc., Merck and Co. Inc., Novartis International AG, Pfizer Inc., Stiefel Laboratories Inc., Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, and UCB SA.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Psoriasis Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Psoriasis Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Psoriasis Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Psoriasis Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Psoriasis Drugs Market?
6. What is the market share of the leading vendors in the Global Psoriasis Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Psoriasis Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of psoriasis
5.1.1.2. Rising geriatric population coupled with growing prevalence of plaque psoriasis and psoriatic arthritis
5.1.1.3. Ease of process of approval of psoriasis drugs
5.1.2. Restraints
5.1.2.1. High cost of treatment
5.1.3. Opportunities
5.1.3.1. Increasing awareness regarding treatment and rising demand for improved healthcare infrastructure
5.1.3.2. Adoption of technologically advanced non-invasive or minimally invasive psoriasis treatment procedures
5.1.4. Challenges
5.1.4.1. Side effects of the medication
5.2. Cumulative Impact of COVID-19
6. Psoriasis Drugs Market, by Therapeutic Class
6.1. Introduction
6.2. Interleukin Inhibitors
6.3. Tumor Necrosis Factor Inhibitor
7. Psoriasis Drugs Market, by Type of Treatment
7.1. Introduction
7.2. Biologic Drugs
7.3. Small Molecule Systemic Drugs
7.4. Tropical Therapies
8. Psoriasis Drugs Market, by Mechanism of Action
8.1. Introduction
8.2. Interleukin Inhibitors
8.3. PDE4 Inhibitors
8.4. TNF Alpha Inhibitors
9. Psoriasis Drugs Market, by Route of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
9.4. Topical
10. Psoriasis Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Psoriasis Drugs Market, by Application
11.1. Introduction
11.2. Arthritis
11.3. Erythrodermic
11.4. Guttate
11.5. Intertriginous
11.6. Nail
11.7. Plaque
11.8. Pustular
12. Americas Psoriasis Drugs Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Psoriasis Drugs Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Psoriasis Drugs Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. AbbVie Inc.
16.1.1. Business Overview
16.1.2. Key Executives
16.1.3. Product & Services
16.2. Amgen Inc.
16.2.1. Business Overview
16.2.2. Key Executives
16.2.3. Product & Services
16.3. AstraZeneca PLC
16.3.1. Business Overview
16.3.2. Key Executives
16.3.3. Product & Services
16.4. Bausch Health Companies Inc.
16.4.1. Business Overview
16.4.2. Key Executives
16.4.3. Product & Services
16.5. Biogen Idec
16.5.1. Business Overview
16.5.2. Key Executives
16.5.3. Product & Services
16.6. C.H. Boehringer Sohn AG & Ko. KG
16.6.1. Business Overview
16.6.2. Key Executives
16.6.3. Product & Services
16.7. Celgene Corporation
16.7.1. Business Overview
16.7.2. Key Executives
16.7.3. Product & Services
16.8. Dr.Reddy’s Laboratories
16.8.1. Business Overview
16.8.2. Key Executives
16.8.3. Product & Services
16.9. Eli Lilly and Company
16.9.1. Business Overview
16.9.2. Key Executives
16.9.3. Product & Services
16.10. Forward Pharma
16.10.1. Business Overview
16.10.2. Key Executives
16.10.3. Product & Services
16.11. Johnson & Johnson Services, Inc.
16.11.1. Business Overview
16.11.2. Key Executives
16.11.3. Product & Services
16.12. Leo Pharma AS
16.12.1. Business Overview
16.12.2. Key Executives
16.12.3. Product & Services
16.13. Merck & Co., Inc.
16.13.1. Business Overview
16.13.2. Key Executives
16.13.3. Product & Services
16.14. Merck and Co. Inc.
16.14.1. Business Overview
16.14.2. Key Executives
16.14.3. Product & Services
16.15. Novartis International AG
16.15.1. Business Overview
16.15.2. Key Executives
16.15.3. Product & Services
16.16. Pfizer Inc.
16.16.1. Business Overview
16.16.2. Key Executives
16.16.3. Product & Services
16.17. Stiefel Laboratories Inc.
16.17.1. Business Overview
16.17.2. Key Executives
16.17.3. Product & Services
16.18. Sun Pharmaceutical Industries Ltd
16.18.1. Business Overview
16.18.2. Key Executives
16.18.3. Product & Services
16.19. Takeda Pharmaceutical Company Limited
16.19.1. Business Overview
16.19.2. Key Executives
16.19.3. Product & Services
16.20. UCB SA
16.20.1. Business Overview
16.20.2. Key Executives
16.20.3. Product & Services
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing